Hyperpigmented Scleroderma-like Lesions under Combined Pembrolizumab and Pemetrexed Treatment of Non-Small Lung Cancer

Immune checkpoint inhibitors (ICI) and other antineoplastic treatment regimens can trigger cutaneous immune-related adverse events (irAEs). There is a tendency for underreporting of such cases, as irAEs are typically perceived mild transient. However, more serious occur which, despite their lower frequency, deserve attention require specific care. Here, we report case extensive hyperpigmented scleroderma-like lesions (SLL) on the extremities under combination with pembrolizumab pemetrexed in patient metastatic non-small cell lung cancer. The present conjunction review current literature underscores potential risk developing SLL anti-PD-1 antibody and/or pemetrexed. Moreover, it possible that this particular synergistically increases SLL. As result, cases may arise future, ICI/pemetrexed might be employed often. drug-induced usually systemic high dose-corticosteroids, physicians should aware an irAE when cancer patients sclerotic fibrotic skin lesions.